SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CLYM

Climb Bio, Inc. (NASDAQ:CLYM)

US · Delayed Price · Currency is USD
Also listed: ELYMHealthcare · Biotechnology
$9.19-$0.09 (-0.97%)
 
Market cap
$540M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 10, 2021
Market Cap$539.80M+422.2%
Revenue (ttm)$0
Net Income-$59.31M-16.9%
EPS-$0.82-7.9%
Shares Out58.74M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume770,180
Open$8.94
Previous Close$9.28
Day's Range$8.90 - $9.40
52-Week Range$1.64 - $18.33
Beta0.07
AnalystsBuy
Price Target$29.45(+220.46%)
Earnings DateMar 4, 2027

About CLYM

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Address
20 William Street, Wellesley Hills, MA, 02481, US
Market Cap
540 million
Employees
28
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.65M
Bought
$779.63K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy0 Hold0 SellAvg target $24.88 (+170.7%)

6 firms rating CLYM in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From CLYM’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-0.97%
5 Days
-9.01%
1 Month
-12.81%
6 Months
-16.45%
1 Year
+422.16%

$CLYM stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CLYM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CLYM's directors and management

Net Shares Purchased by Insiders−400k−200k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CLYM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CLYM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CLYM from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CLYM

VTIVanguard Morningstar Total Stock Market ETF$15.01M
XBIState Street SPDR S&P Biotech ETF$10.24M
IWMiShares Russell 2000 ETF$9.03M
VXFVanguard Extended Market ETF$4.69M
VFMOVanguard U.S. Momentum Factor ETF$2.83M
VTWOVanguard Russell 2000 ETF$2.23M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CLYM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
13.44
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
3
Sells
6
Buy Value
$779.63K
Distinct Buyers
1

Insider Score Trend Over Time

+0.0 since Oct 4
0255075100Oct 4 — Insider Score 0.0Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

VAMOCambria Value and Momentum ETF1.50%
BBCVirtus Biotech Clinical Trials ETF0.79%
SBIOALPS Medical Breakthroughs ETF0.41%
AFSMFirst Trust Active Factor Small Cap ETF0.36%
TDNAT. Rowe Price Biotech ETF0.31%
VFMOVanguard U.S. Momentum Factor ETF0.15%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.12%
XBIState Street SPDR S&P Biotech ETF0.12%
IWCiShares Micro-Cap ETF0.11%
FSMOFidelity Fundamental Small-Mid Cap ETF0.11%
FFSMFidelity Fundamental Small-Mid Cap ETF0.11%
TNXTT. Rowe Price Innovation Leaders ETF0.11%

Weight is the stock’s share of each fund’s holdings.